Nuvalent (NASDAQ:NUVL) Insider Henry Pelish Sells 2,496 Shares of Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Henry Pelish sold 2,496 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total transaction of $242,910.72. Following the completion of the transaction, the insider directly owned 68,552 shares of the company’s stock, valued at $6,671,480.64. This trade represents a 3.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Nuvalent Price Performance

NUVL stock opened at $106.82 on Thursday. Nuvalent, Inc. has a 1 year low of $55.53 and a 1 year high of $112.88. The stock has a market cap of $7.77 billion, a price-to-earnings ratio of -20.08 and a beta of 1.32. The company has a 50 day simple moving average of $102.64 and a 200 day simple moving average of $88.91.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period in the previous year, the company earned ($1.28) EPS. On average, equities research analysts anticipate that Nuvalent, Inc. will post -3.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Wedbush restated an “outperform” rating and issued a $125.00 price target (up from $120.00) on shares of Nuvalent in a research report on Monday, November 17th. Truist Financial set a $140.00 price objective on shares of Nuvalent in a research note on Monday, November 24th. Guggenheim increased their price objective on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a research report on Wednesday, October 8th. Fifteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $138.33.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James R. Porter sold 17,890 shares on Jan. 5 at an average $97.32 for $1.741M (ownership down ~5.85%). SEC Filing
• Negative Sentiment: CEO James R. Porter sold an additional 9,543 shares on Jan. 6 at ~$97.16 for $927k (ownership down ~3.31% after the sale). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (~$412k) and 3,181 shares on Jan. 6 at $97.16 (~$309k), reducing her stake by ~4.75% and ~3.75% respectively. SEC Filing
• Negative Sentiment: Director/insider Christopher D. Turner sold 4,236 shares on Jan. 5 and 3,181 shares on Jan. 6 at ~ $97.32 / $97.16, cutting his stake by roughly 6.8% and 5.5%. SEC Filing
• Negative Sentiment: Insider Deborah A. Miller sold 4,363 shares on Jan. 5 (~$424.6k) and 2,589 shares on Jan. 6 (~$251.5k), reducing her position by ~8.9% and ~5.8%. SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,496 shares on Jan. 5 (~$242.9k) and 2,664 shares on Jan. 6 (~$258.9k), trimming his stake by ~3.5% and ~3.9%. SEC Filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NUVL. Vanguard Group Inc. grew its stake in Nuvalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 4,605,007 shares of the company’s stock worth $398,241,000 after purchasing an additional 80,883 shares during the period. Wellington Management Group LLP lifted its stake in Nuvalent by 46.0% in the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after buying an additional 724,491 shares during the period. State Street Corp boosted its holdings in shares of Nuvalent by 4.2% during the 2nd quarter. State Street Corp now owns 1,490,279 shares of the company’s stock worth $113,708,000 after buying an additional 59,620 shares in the last quarter. Commodore Capital LP grew its position in shares of Nuvalent by 1.8% during the 3rd quarter. Commodore Capital LP now owns 1,400,000 shares of the company’s stock worth $121,072,000 after buying an additional 25,000 shares during the period. Finally, RA Capital Management L.P. acquired a new stake in shares of Nuvalent during the 3rd quarter worth approximately $107,794,000. 97.26% of the stock is owned by institutional investors and hedge funds.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.